Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries

Claes-Göran Östenson,1 Stephan Matthaei,2 Matthew Reaney,3 Thure Krarup,4 Bruno Guerci,5 Jacek Kiljanski,6 Carole Salaun-Martin,7 Hélène Sapin,7 David Bruhn,8 Chantal Mathieu,9 Michael Theodorakis10 1Department of Molecular Medicine and Surgery, Karolinska Ins...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c6b427517eeb4deabb630438e1dd8a79
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6b427517eeb4deabb630438e1dd8a79
record_format	dspace
spelling	oai:doaj.org-article:c6b427517eeb4deabb630438e1dd8a792021-12-02T05:10:08ZTreatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries1178-7007https://doaj.org/article/c6b427517eeb4deabb630438e1dd8a792013-04-01T00:00:00Zhttp://www.dovepress.com/treatment-outcomes-after-initiation-of-exenatide-twice-daily-or-insuli-a12871https://doaj.org/toc/1178-7007Claes-Göran Östenson,1 Stephan Matthaei,2 Matthew Reaney,3 Thure Krarup,4 Bruno Guerci,5 Jacek Kiljanski,6 Carole Salaun-Martin,7 Hélène Sapin,7 David Bruhn,8 Chantal Mathieu,9 Michael Theodorakis10 1Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; 2Diabetes-Center Quakenbrück, Quakenbrück, Germany; 3Eli Lilly, Windlesham, Surrey, UK; 4Department of Endocrinology I, Bispebjerg Hospital, Copenhagen, Denmark; 5Diabetology, Metabolic Diseases and Nutrition, Brabois Hospital, CHU Nancy, and INSERM CIC, ILCV, Vandoeuvre Lès Nancy, France; 6Eli Lilly, Warsaw, Poland; 7Eli Lilly, Neuilly Cedex, France; 8Eli Lilly, San Diego, California, USA; 9Department of Endocrinology, UZ Gasthuisberg, Leuven, Belgium; 10Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece* *Michael Theodorakis was affiliated with the institution shown at the time of the study, but has since left this institution Objective: The CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy (CHOICE) study assessed time to, and reasons for, significant treatment change after patients with type 2 diabetes (T2DM) initiated their first injectable glucose-lowering therapy (exenatide twice daily [BID] or insulin) in routine clinical practice, and these patients’ clinical outcomes, in six European countries. This paper reports interim data from the first 12 months of the study. Research design and methods: CHOICE (NCT00635492) is a prospective, noninterventional, observational study. Clinical data were collected at initiation of first injectable therapy and after approximately 3, 6, and 12 months. Results: Of 2497 patients enrolled in CHOICE, 1096 in the exenatide BID and 1239 in the insulin cohorts had ≥1 post-baseline assessment and were included in this analysis. Overall, 32.2% of the exenatide BID cohort and 29.1% of the insulin cohort (Kaplan–Meier estimates) had significant treatment change during the first 12 months, most commonly discontinuing injectable therapy or adding new T2DM therapy, respectively. Glycemic control improved in both cohorts, but weight loss occurred only in the exenatide BID cohort (mean change –3.3 kg). Hypoglycemia occurred in 13.2% of the exenatide BID cohort and 28.6% of the insulin cohort (82.8% and 55.6% of these patients, respectively, received sulfonylureas). The post hoc endpoint of glycated hemoglobin < 7%, no weight gain, and no hypoglycemia was attained at 12 months by 24.3% and 10.3% of patients who had data at 12 months and who were receiving exenatide BID and insulin, respectively. Conclusion: About 30% of patients in CHOICE changed treatment in the first 12 months after initiation of first injectable therapy (exenatide BID or insulin). Overall, both cohorts achieved improved glycemic control, which was accompanied by a mean weight loss in the exenatide BID cohort. Keywords: type 2 diabetes mellitus, exenatide, insulin, injectable therapyOstenson CGMatthaei SReaney MKrarup TGuerci BKiljanski JSalaun-Martin CSapin HBruhn DMathieu CTheodorakis MDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2013, Iss default, Pp 171-185 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Ostenson CG Matthaei S Reaney M Krarup T Guerci B Kiljanski J Salaun-Martin C Sapin H Bruhn D Mathieu C Theodorakis M Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
description	Claes-Göran Östenson,1 Stephan Matthaei,2 Matthew Reaney,3 Thure Krarup,4 Bruno Guerci,5 Jacek Kiljanski,6 Carole Salaun-Martin,7 Hélène Sapin,7 David Bruhn,8 Chantal Mathieu,9 Michael Theodorakis10 1Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; 2Diabetes-Center Quakenbrück, Quakenbrück, Germany; 3Eli Lilly, Windlesham, Surrey, UK; 4Department of Endocrinology I, Bispebjerg Hospital, Copenhagen, Denmark; 5Diabetology, Metabolic Diseases and Nutrition, Brabois Hospital, CHU Nancy, and INSERM CIC, ILCV, Vandoeuvre Lès Nancy, France; 6Eli Lilly, Warsaw, Poland; 7Eli Lilly, Neuilly Cedex, France; 8Eli Lilly, San Diego, California, USA; 9Department of Endocrinology, UZ Gasthuisberg, Leuven, Belgium; 10Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece* *Michael Theodorakis was affiliated with the institution shown at the time of the study, but has since left this institution Objective: The CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy (CHOICE) study assessed time to, and reasons for, significant treatment change after patients with type 2 diabetes (T2DM) initiated their first injectable glucose-lowering therapy (exenatide twice daily [BID] or insulin) in routine clinical practice, and these patients’ clinical outcomes, in six European countries. This paper reports interim data from the first 12 months of the study. Research design and methods: CHOICE (NCT00635492) is a prospective, noninterventional, observational study. Clinical data were collected at initiation of first injectable therapy and after approximately 3, 6, and 12 months. Results: Of 2497 patients enrolled in CHOICE, 1096 in the exenatide BID and 1239 in the insulin cohorts had ≥1 post-baseline assessment and were included in this analysis. Overall, 32.2% of the exenatide BID cohort and 29.1% of the insulin cohort (Kaplan–Meier estimates) had significant treatment change during the first 12 months, most commonly discontinuing injectable therapy or adding new T2DM therapy, respectively. Glycemic control improved in both cohorts, but weight loss occurred only in the exenatide BID cohort (mean change –3.3 kg). Hypoglycemia occurred in 13.2% of the exenatide BID cohort and 28.6% of the insulin cohort (82.8% and 55.6% of these patients, respectively, received sulfonylureas). The post hoc endpoint of glycated hemoglobin < 7%, no weight gain, and no hypoglycemia was attained at 12 months by 24.3% and 10.3% of patients who had data at 12 months and who were receiving exenatide BID and insulin, respectively. Conclusion: About 30% of patients in CHOICE changed treatment in the first 12 months after initiation of first injectable therapy (exenatide BID or insulin). Overall, both cohorts achieved improved glycemic control, which was accompanied by a mean weight loss in the exenatide BID cohort. Keywords: type 2 diabetes mellitus, exenatide, insulin, injectable therapy
format	article
author	Ostenson CG Matthaei S Reaney M Krarup T Guerci B Kiljanski J Salaun-Martin C Sapin H Bruhn D Mathieu C Theodorakis M
author_facet	Ostenson CG Matthaei S Reaney M Krarup T Guerci B Kiljanski J Salaun-Martin C Sapin H Bruhn D Mathieu C Theodorakis M
author_sort	Ostenson CG
title	Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
title_short	Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
title_full	Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
title_fullStr	Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
title_full_unstemmed	Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
title_sort	treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from choice in six european countries
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/c6b427517eeb4deabb630438e1dd8a79
work_keys_str_mv	AT ostensoncg treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT matthaeis treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT reaneym treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT krarupt treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT guercib treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT kiljanskij treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT salaunmartinc treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT sapinh treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT bruhnd treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT mathieuc treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries AT theodorakism treatmentoutcomesafterinitiationofexenatidetwicedailyorinsulininclinicalpractice12monthresultsfromchoiceinsixeuropeancountries
_version_	1718400558794014720

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries

Ejemplares similares